Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.07B | $2.16B | $2.29B | $2.31B | $2.55B | $2.92B | $2.80B | $2.67B | $2.57B | $2.58B |
| Revenue growth | — | 4.4% | 6.0% | 1.0% | 10.1% | 14.8% | -4.1% | -4.7% | -3.9% | 0.7% |
| Gross profit | $1.14B | $1.19B | $1.22B | $1.26B | $1.44B | $1.64B | $1.57B | $1.43B | $1.38B | $1.34B |
| Gross margin | 55.0% | 55.0% | 53.4% | 54.4% | 56.5% | 56.1% | 55.9% | 53.4% | 53.7% | 51.9% |
| Operating income | $55.7M | $119M | -$103M | $230M | $421M | $500M | $483M | $338M | $269M | $47.2M |
| Operating margin | 2.7% | 5.5% | -4.5% | 9.9% | 16.6% | 17.1% | 17.2% | 12.6% | 10.5% | 1.8% |
| Net income | $26.0M | $122M | $366M | $1.76B | $3.81B | $4.25B | -$3.63B | -$637M | -$1.84B | $760M |
| Net margin | 1.3% | 5.7% | 16.0% | 76.1% | 149.8% | 145.6% | -129.5% | -23.9% | -71.9% | 29.4% |
| EPS (diluted) | $0.88 | $4.07 | $12.10 | $58.27 | $126.47 | $140.83 | -$121.79 | -$21.82 | -$65.36 | $27.85 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $216M | $104M | $285M | $458M | $585M | $669M | $194M | $375M | $455M | $532M |
| Capital expenditures | $141M | $111M | $130M | $98.5M | $109M | $134M | $113M | $157M | $166M | $158M |
| Free cash flow | $74.6M | -$7.20M | $156M | $359M | $476M | $536M | $81.6M | $218M | $290M | $375M |
| Share buybacks | $0.00 | $2.92M | $48.9M | $28.0M | $100M | $50.0M | $216M | $429M | $204M | $296M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $456M | $384M | $432M | $661M | $662M | $471M | $434M | $404M | $488M | $530M |
| Total assets | $3.85B | $4.27B | $5.61B | $8.01B | $13.0B | $17.8B | $13.5B | $12.3B | $9.36B | $10.6B |
| Total liabilities | $1.27B | $1.34B | $1.59B | $2.25B | $3.09B | $4.11B | $3.89B | $3.56B | $2.79B | $3.12B |
| Long-term debt | — | — | — | — | — | — | $1.20B | $1.20B | $1.20B | $1.20B |
| Shareholders' equity | $2.58B | $2.93B | $4.02B | $5.76B | $9.89B | $13.7B | $9.62B | $8.74B | $6.57B | $7.45B |
| Retained earnings | $1.83B | $1.83B | $3.72B | $5.47B | $9.27B | $13.5B | $9.90B | $9.26B | $7.42B | $8.18B |
| Shares (wtd avg diluted) | 29.6M | 30.0M | 30.2M | 30.2M | 30.2M | 30.2M | 29.8M | 29.2M | 28.2M | 27.3M |
Every figure is extracted from BIO-RAD LABORATORIES, INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.